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Background: Requisites for an efficacious tuberculosis (TB) vaccine are a minimal genomic diversity among infectious
Mycobacterium tuberculosis strains for the selected antigen, and the capability to induce robust T-cell responses in the
majority of human populations. A tool in the identification of putative T-cell epitopes is in silico prediction of major
histocompatibility complex (MHC)-peptide binding. Candidate TB vaccine antigen Mtb72F and its successor M72
are recombinant fusion proteins derived from Mtb32A and Mtb39A (encoded by Rv0125 and Rv1196, respectively).
Adjuvanted Mtb72F and M72 candidate vaccines were shown to induce CD4+ T-cell responses in European, US,
African and Asian populations.
Methods: Sequence conservation of Mtb32A, Mtb39A, Mtb72F and M72 among 46 strains (prevalent Mycobacterium
strains causing human TB disease, and H37Ra) was assessed by multiple alignments using ClustalX. For Mtb32A,
Mtb39A and Mtb72F, 15-mer human leukocyte antigen (HLA)-class II-binding peptides were predicted for 158
DRB1 alleles prevailing in populations with high TB burden, 6 DRB3/4/5, 8 DQ and 6 DP alleles, using NetMHCII-
pan-3.0. Results for 3 DRB1 alleles were compared with previously published allele-matched in vitro binding data.
Additional analyses were done for M72. Nonameric MHC class I-binding peptides in Mtb72F were predicted for three
alleles representative of class I supertypes A02, A03 and B07, using seven prediction algorithms.
Results: Sequence identity among strains was ≥98 % for each protein. Residue changes in Mtb39A comprised primarily
single residue or nucleotide insertions and/or deletions in repeat regions, and were observed in 67 % of strains. For
Mtb72F, 156 DRB1, 6 DRB3/4/5, 7 DQ and 5 DP alleles were predicted to contain at least one MHC class II-binding
peptide, and class I-binding peptides were predicted for each HLA-A/B allele. Comparison of predicted MHC-II-binding
peptides with experimental data indicated that the algorithm’s sensitivity and specificity were variable among alleles.
Conclusions: The sequences from which Mtb72F and M72 are derived are highly conserved among representative
Mycobacterium strains. Predicted putative T-cell epitopes in M72 and/or Mtb72F covered a wide array of HLA alleles. In
silico binding predictions for class I- and II-binding putative epitopes can be complemented with biochemical verification
of HLA binding capacity, processing and immunogenicity of the predicted peptides.Background
Genetic variation in antigen components of vaccines at
the pathogen level as well as in the host (the latter relating
to the polymorphism in the human leukocyte antigen
[HLA]), are major determinants for human vaccine effi-
cacy. Mycobacterium tuberculosis (Mtb) is the causative* Correspondence: marie-cecile.mortier@gsk.com
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cious TB vaccine to be used in populations world-wide are
a minimal genomic variation of the target antigen among
different Mtb strains, and the ability of the antigen’s con-
tents of peptides to bind to the largest possible subset of
HLA alleles in the host populations. The TB vaccine
should also be able to induce robust T-cell responses [1].
While CD4+ T cells are thought to take center stage in the
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quently, the selection of a vaccine antigen is in part focused
on the abundance of HLA class I and class II-binding epi-
topes, which may be indicative of its immunogenicity.
HLA-peptide binding is a prerequisite for a putative epi-
tope, linked to its correct processing and immunogenicity,
and in silico prediction of this binding has become a tool
in vaccine design. Predictive computer algorithms are gen-
erally trained by databases of experimentally validated epi-
topes with T-cell stimulation potential, such as SYFPEITHI
[2] or the Immune Epitope Database (IEDB) [3]. For Mtb,
the IEDB lists predominantly major histocompatibility
complex class II (MHC-II)-restricted epitopes of the
H37Rv strain [4], and the number of identified MHC
class I (MHC-I)-restricted Mtb epitopes is limited [5].
Moreover, few Mtb epitopes have been identified for al-
leles prevailing in populations in TB-endemic regions.
The known epitopes that are targeted by human T cell-
mediated immune responses cover only 4 % of the Mtb
proteome [6].
The pe/ppe gene family, which includes ~170 members,
comprises approximately 10 % of the Mtb genome [7]. It
has been suggested that proteins secreted by these genes
aid in Mtb infection [8], and that Mtb39A (encoded by
Rv1196/ppe18) has a role in Mtb virulence [9, 10]. Since in-
fection can induce CD4+ and CD8+ T-cell responses to
various PE/PPE proteins, some of these proteins have been
evaluated as potential TB vaccine antigens [7, 11]. The vac-
cine antigen Mtb72F is a recombinant polyprotein derived
from the H37Rv-expressed proteins Mtb39A and Mtb32A
(the latter protein is a putative serine protease encoded by
pepA/Rv0125) [12]. Both genes are present in both virulent
and avirulent strains of the Mtb complex, and in bacille
Calmette-Guérin (BCG) [13, 14]. The Mtb72F construct
was generated by linking the carboxyl-terminal fragment of
Mtb32A (Mtb32C), Mtb39A, and the amino-terminal frag-
ment of Mtb32A excluding the signal sequence (Mtb32N)
[12]. In a clinical study, the vaccine candidate Mtb72F in-
duced comparable magnitudes of Mtb32A- and Mtb39A-
specific CD4+ T-cell responses [15]. Collectively, at least 10
CD4+ or CD8+ T-cell epitopes (which were recognized by
PBMC from human PPD-positive donors) have been iden-
tified in Mtb39A [14, 16], and a mouse CD8+ T-cell epi-
tope was identified within Mtb32C [12, 17].
Several Mtb72F peptides have been experimentally char-
acterized to bind to one of three common HLA class II al-
leles (DRB1*01:01, 15:01 and 04:01) [18], or to the HLA
class I allele B44 [16]. The successor of Mtb72F, M72, was
generated from the Mtb72F sequence by introducing a
point mutation in order to improve the long-term stability
of the purified bulk of Mtb72F, and by modification of the
N-terminal poly-histidine (poly-His) sequence. In clinical
studies, these modifications were shown to have no effect
on the antigen’s immunogenicity with respect to cell-mediated or humoral responses [19]. Indeed, antigen-
specific CD4+ T-cell and antibody responses were elicited
by AS02-adjuvanted Mtb72F vaccines in various adult
populations [15, 19–21], and by AS01-adjuvanted M72
vaccines in populations of healthy adults in TB-endemic
and non-endemic regions [19, 22, 23], HIV-1-infected
adults in Switzerland [24], and healthy infants in The
Gambia [25]. Consequently, M72 has been selected for
further vaccine development.
The objectives of this in silico study were (1), to assess
the sequence conservation of Mtb32A, Mtb39A, Mtb72F
and M72, and (2), to predict MHC-I binding for nonameric
peptides in Mtb72F, and MHC-II binding for 15-mer pep-
tides in Mtb72F, Mtb32A and Mtb39A. The predictions fo-
cused on Mtb72F rather than M72 in order to allow
comparison with previous prediction studies [26, 27], and
additional evaluations were performed to assess the impact
of the alterations introduced in Mtb72F to generate M72.
MHC-II-binding predictions were evaluated for DRB1 al-
leles prevailing in populations with a high TB burden, and
for DRB3/4/5, DP and DQ alleles. Last, we compared our
prediction results obtained for three DRB1 alleles with
allele-matched, experimentally derived MHC-II binding
data described in [18].
Our findings suggested that the Mtb72F and M72 se-
quences are highly conserved among representative Myco-
bacterium strains and that the putative T-cell epitopes
predicted for these two proteins cover a wide array of
HLA class I and II alleles, while highlighting the limita-
tions of in silico epitope predictions in general.
Results
Sequence conservation analysis for Mtb32A, Mtb39A,
Mtb72F and M72
Using sequence similarity search programs, we assessed the
similarity of H37Rv-derived Mtb32A and Mtb39A among
genomes of Mycobacterium strains causing human TB
disease, and H37Ra. For the 40 strains for which both se-
quences were available, similarity was also evaluated for the
Mtb72F and M72 sequences constructed in silico. Further-
more, the presence of nucleotide and amino acid changes
was evaluated for Mtb39A, given the relatively high fre-
quency of sequence polymorphism reported for this pro-
tein [28, 29]. The strains evaluated included clinical isolates
and representatives of all presently available Mtb strains,
and comprised representatives of five of the six geograph-
ical lineages identified in a molecular phylogeny of the Mtb
complex, which cover the predominant part of the Mtb
geographical distribution [30].
For Mtb39A, we observed mainly single residue or nu-
cleotide insertions and/or deletions with minor conse-
quences for amino acid sequences, although amino acid
changes were detected in 67 % of strains assessed (Table 1).
Indeed, amino acid sequence comparisons revealed an
Table 1 Similarity of Mtb32A, Mtb39A, Mtb72F and M72 among selected Mycobacterium strains
Lineagea Strains NCBI Accession
number
Mtb39A Mtb39A Mtb32A Mtb72F M72
No. of
aa changes
No. of aa/nt, position (pos) % identity
Insertions Deletions Frameshifts
1 T17 PRJNA55273 3 99.23 94.37 96.79 96.65
T46 PRJNA55875 3 99.23b - - -
T92 PRJNA55099 3 99.23 100 99.58 99.44
EAS054 PRJNA55133 117 1 nt, pos 811 1, pos 270-391 68.92 100 84.37 84.23
2 94_M4241A PRJNA55095 0 100 100 100 99.86
210
(Mtb Beijing)
PRJNA42617 30 1 aa, pos 274 91.3 100 95.4 95.26
02_1987 PRJNA55097 1 99.74 100 99.86 99.72
T85 PRJNA55131 1 99.74 100 99.86 99.72
W-148
(Mtb. Beijing;MDR)
PRJNA182020 1 99.74 100 99.86 99.72
3 - - - - -
4 CDC1551 PRJNA57775 0 100 100 100 99.86
C PRJNA54359 0 100b - - -
F11 PRJNA58417 1 99.74 100 99.86 99.72
GM1503 PRJNA55271 - - - - - 100b - -
H37Rac PRJNA58853 62 1 nt, pos 922 1, pos 309–391 82.28 100 90.56 90.42
Haarlem PRJNA54453 0 100 100 100 99.86
KZN1435 (MDR) PRJNA59069 0 100 100 100 99.86
98R604INHRIFEM PRJNA55399 0 100 100 100 99.86
5 CPHL_A
(M. africanum)
PRJNA55877 4 1 aa, pos 274 98.72 100 99.3 99.16
6 K85
(M. africanum)
PRJNA55879 3 2 aa, pos 162 1 aa, pos 274 98.48 100 99.17 99.03
n.d. SUMu001 PRJNA51927 8 1 aa, pos 274 97.70 100 98.75 98.61
SUMu002 PRJNA51925 - - - - - 100b - -
SUMu003 PRJNA51931 2 99.49 100 99.72 99.58
SUMu004 PRJNA51933 2 1 aa, pos 274 99.23 100 99.58 99.44
SUMu005 PRJNA51935 2 1 aa, pos 274 99.23 100 99.58 99.44
SUMu006 PRJNA91937 2 99.49 100 99.72 99.58
SUMu008 PRJNA51941 - - - - - 100b - -
SUMu010 PRJNA51945 - - - - - 100b - -
KZN605 (XDR) PRJNA54947 0 100 100 100 99.86
KZN4207 PRJNA83619 0 100 100 100 99.86
KZNR506 (XDR) PRJNA47489 0 100 100 100 99.86
KZNV2475
(MDR)
PRJNA47491 1 99.74 100 99.86 99.72
UT205 PRJNA162183 0 100 100 100 99.86
BTB05-552 PRJNA51871 0 100 100 100 99.86
BTB05-559 PRJNA51873 0 100 100 100 99.86
S96-129 PRJNA51869 0 100 100 100 99.86
CCDC5079 PRJNA161943 1 99.74 100 99.86 99.72
CCDC5180 PRJNA161941 1 99.74 100 99.86 99.72
CTRI-2 PRJNA161997 0 100 100 100 99.86
CTRI-4 (XDR) PRJNA43175 3 99.23 100 99.58 99.44
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Table 1 Similarity of Mtb32A, Mtb39A, Mtb72F and M72 among selected Mycobacterium strains (Continued)
R1207 (MDR) PRJNA46669 1 99.74 100 99.86 99.72
X122 (pre-XDR) PRJNA46667 1 99.74 100 99.86 99.72
NA-A0008 PRJNA168604 6 98.47 100 99.58 99.44
NA-A0009 PRJNA168605 3 99.23 100 99.16 99.02
HN878 PRJNA46665 3 99.23 100 99.58 99.44
RGTB423 PRJNA162179 2 99.23 85.63 92.48 92.34
RGTB327 PRJNA157907 24 1 nt, pos 480 1 nt, pos 464 1, pos 139–155 93.91 100 96.67 96.53
2 nt, pos 951 1 nt, pos 468 1, pos 314–316
1 nt, pos 959 1 nt, pos 469
1 nt, pos 470
1 nt, pos 475
Affected Strains;
no (%)
28 (67) 3 (7) 8 (19) 3 (7)
Average %
identity
98.08 99.55 98.71 98.57
aLineages as defined in ref. [30]: no. 1: The Philippines / rim of the Indian Ocean; no. 2: East Asia; no. 3: India / East Africa; no. 4: Europe / Americas; no. 5 and no. 6: West
African 1 and 2, respectively. n.d., not defined. MDR, multiple drug-resistant; (pre-)XDR, (pre-)extensively drug-resistant. aa, amino acid(s); nt, nucleotide(s). bEvaluations not
performed for Mtb72F/M72 as a complete sequence was only available for one of the two genes. % identity = (number of identical residues / length of alignment) x100, as
calculated from multiple alignment comparisons. Mtb39A genome sequences were derived from complete genomes (chromosomes; highlighted in bold) or assembled
partial genomes (scaffolds/contigs; normal font). cLaboratory strain H37Ra was used as reference
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tity for 13 strains and at least 91 % identity among all
strains excluding EAS054 and H37Ra. The latter strains
contained one frameshift each, both associated with
major amino acid changes of 117 and 62 residues, re-
spectively, and consequently also with lower similarity
(69 and 82 %, respectively). Relative to Mtb39A, se-
quence identity was higher for Mtb32A (i.e., 99.6 % on
average, and 100 % for 42 of the 44 strains assessed),
consistent with earlier reports [28].
Mtb32A and Mtb39A sequences in 13 clinical isolates
were identical to those in Mtb72F, and 84–99.9 % se-
quence identity was observed for the remaining strains.
Among the three extensively drug-resistant (XDR), 1 pre-
XDR and four multiple drug-resistant (MDR) strains
assessed, percentages identity for Mtb72F were at least
99.6 %. Overall, percentages identity were 0.14 % (1/718)
lower for M72 than for Mtb72F due to the introduced
point mutation in M72, and exceeded 98 % for both anti-
gens in at least one strain per selected Mtb lineage.
MHC-II-binding peptides in Mtb32A, Mtb39A and Mtb72F
A computerized algorithm (NetMHCIIpan-3.0) was used
to compute MHC-II binding predictions for 15-mer pep-
tides in Mtb72F and (H37Rv) Mtb32A and Mtb39A, for
158 HLA-DRB1, 6 DRB3/4/5, 8 DQ and 6 DP alleles. The
DRB1 alleles were selected based on their presence in
populations in four regions with a high TB prevalence
(Northern, Southern and North-Eastern India and China)
and in the native population of Sub-Saharan Africa, which
has a high TB incidence. The 6 most common DRB3/4/5
alleles [31] and the subset of DQ/DP molecules that arepresent in at least 85 % of populations worldwide [32, 33]
were also included, and together our selection contained
the full panel of 46 DR, DP and DQ alleles reported to col-
lectively cover almost 90 % of populations worldwide [31].
HLA-II binding peptides predicted for Mtb72F were
found to cover a wide array of alleles (Additional file 1).
For DRB1*15 and DRB1*16, which have been linked to
susceptibility to TB in Indian populations [34, 35], we
predicted an average of 64 binding peptides in Mtb72F
per allele for the three defined Indian regions. Across
geographical regions, the highest numbers of binding
peptides for Mtb72F were predicted for DRB1*01:02,
01:04, 08:10, 08:06, 01:01 and 01:08, i.e., 533–468 pep-
tides/allele, or 0.65-0.75/allele after normalization of the
results with respect to the different protein lengths of
Mtb32A, Mtb39A and Mtb72F (Fig. 1). Average numbers
of predicted binding peptides per allele in Mtb72F were
highest in Sub-Saharan Africa (163 per allele) followed by
the individual Indian regions (115–143 per allele) and
China (131 per allele) (Table 2). There was a trend for
higher numbers of binding peptides for Mtb39A relative
to Mtb32A.
Across regions, no peptides were predicted to bind to
five alleles (DRB1*03:02, 04:07, 14:10, 14:14 and 14:44)
for Mtb32A, and to two alleles (DRB1*16:04 and 03:02)
for Mtb39A. Consequently, binding peptides were also
not predicted for DRB1*16:04 and 03:02 for Mtb72F,
since for DRB1*16:04 all binding peptides were predicted
to be located in the Mtb32A signal sequence (which is
absent in Mtb72F), while for DRB1*03:02 no binding pep-
tides were predicted for any part of Mtb32A or Mtb39A.


























































































































































































































































































































































































































































































































































Fig. 1 Numbers of predicted HLA class II-binding peptides for Mtb32A, Mtb39A and Mtb72F. HLA-II binding predictions were generated for 15-mer
peptides (overlapping by 14 amino acids) of Mtb32A, Mtb39A and Mtb72F using NetMHCIIpan-3.0, for 158 DRB1 alleles. Results were normalized with
respect to the different protein lengths of Mtb32A, Mtb39A and Mtb72F (i.e., 355, 391 and 729 amino acids, respectively)
Mortier et al. BMC Immunology  (2015) 16:63 Page 5 of 14Chinese and Indian populations (as extracted from a public
database [36]) are relatively low for DRB1*16:04 (ranging
from 0.0-0.6 %) and higher for DRB1*03:02 (ranging from
0.0–17.2 %; Additional file 2).
For the 6 DRB3/4/5, 8 HLA-DQ and 6 HLA-DP mole-
cules, we predicted up to 145, 614 and 170 binding
peptides in Mtb72F per allele, respectively (Table 3).
Binding peptides in Mtb72F were predicted for each
DRB3/4/5 and DP/DQ allele assessed, with the excep-
tion of DQA1*02:01-DQB1*02:01 (for which there were
no prediction results for any of the four proteins
assessed) and DPA1*02:02-DPB1*05:01 (for which
all predicted peptides were located in the Mtb32A
signal sequence). Worldwide, genotypic frequencies of
DQA1*02:01-DQB1*02:01 and DPA1*02:02-DPB1*05:01
are 6 % and 12 %, respectively [37], but for the popula-
tions assessed, no frequencies of these alleles have been
reported in the used database (Additional file 2). For
DQA1*02:01-DQB1*02:01 in haplotype with DRB1*07:01
(either alone or with DPB1*02:01, 03:01 or 17:01) fre-
quencies in various populations ranged from 1–15 %.
For DRB1*07:01, and thus also for the DRB1*07:01-DQA1*02:01-DQB1*02:01 haplotypes, 181 peptides
were predicted in Mtb72F (Additional file 1), with
potentially higher numbers for haplotypes that also
include DPB1*02:01 (Table 3).Impact of the alterations made to construct Mtb72F and
M72, on MHC-II binding predictions
Several alterations have been introduced into the native
Mtb32A sequence in order to construct Mtb72F [12];
summarized in Table 4), and hence we have assessed the
potential impact thereof on the prediction results for
Mtb72F. We observed that the alterations resulted in a
reduction of 42 predicted binding peptides, as well as in 1
and 18 additional predicted (non-Mtb) binding peptides
owing to the addition of the poly-His tag and the hinge se-
quences respectively. As described in the previous section,
no binding peptides were predicted after the alterations
for one allele (DRB1*16:04) due to the deletion of the
Mtb32A signal sequence. Additional evaluations were
performed to assess the impact of the modifications
introduced into Mtb72F in order to generate M72,
Table 2 MHC class II-binding peptide predictions for common DRB1 alleles in high-TB burden regions
Region/Alleles
assessed (N)
Protein Predicted epitopes (N) DRB1 alleles without predicted epitope
Total Average/allele N Allele
Overall Mtb32A 8792 56 5 *03:02, *04:07, *14:10, *14:14, *14:44
(N = 158) Mtb39A 14675 93 2 *03:02, *16:04
Mtb72F 22065 140 2 *03:02, *16:04a
China Mtb32A 5873 40 5 *03:02, *04:07, *14:10, *14:14, *14:44
(N = 146) Mtb39A 12794 88 2 *03:02, *16:04
Mtb72F 19109 131 2 *03:02, *16:04a
N. India Mtb32A 2595 55 2 *03:02, *04:07
(N = 47) Mtb39A 4516 96 1 *03:02
Mtb72F 6733 143 1 *03:02a
S. India Mtb32A 1087 43 0
(N = 25) Mtb39A 1993 80 1 *16:04
Mtb72F 2868 115 1 *16:04a
N.E. India Mtb32A 2155 51 2 *03:02, *04:07
(N = 42) Mtb39A 3517 84 1 *03:02
Mtb72F 5298 126 1 *03:02a
India (Total) Mtb32A 2807 37 2 *03:02, *04:07
(N = 76) Mtb39A 4634 61 2 *03:02, *16:04
Mtb72F 6876 90 2 *03:02, *16:04a
S.S. Africab Mtb32A 4447 67 1 *03:02
(N = 66) Mtb39A 6977 106 1 *03:02
Mtb72F 10737 163 1 *03:02a
Prediction results represent the sum of the weak and strong binders. aAllele frequencies in the populations assessed are included in Additional file 2. bS.S. Africa,
Sub-Saharan Africa, native population only
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quence from MHHHHHH to MHH, and the substitu-
tion of one serine residue for an alanine residue.
Neither of the modifications resulted in a change in
the number of alleles with at least one predicted pu-
tative epitope. No putative epitopes were predicted to
be present in the MHH tag, and thus this modifica-
tion of the poly-His tag resulted in the loss of the
above described non-Mtb binding peptide predicted
for the Mtb72F poly-His tag.Comparison of MHC-II binding predictions for 3 DRB1
alleles with experimental data
We compared our prediction results for three common
HLA class II alleles (DRB1*01:01, 04:01 and 15:01) with
binding data obtained in vitro for Mtb32A and Mtb39A
from Maeurer et al. [18]. In the latter study, the binding
to soluble recombinant HLA-II monomers of three al-
leles was experimentally determined for 7466 15-mer
Mtb peptides.
For Mtb72F predictions, the algorithm’s sensitivity
was higher for DRB1*01:01 than for DRB1*04:01 orDRB1*15:01, as 74, 28 and 33 % respectively of the
allele-matched experimentally identified binding pep-
tides were also predicted by the algorithm, while the re-
verse was found for the specificities (which were 34, 81
and 90 %, respectively; Table 5). The same trends were
observed for the prediction results obtained for Mtb32A
and Mtb39A separately.MHC-I binding predictions for nonameric peptides in
Mtb72F
HLA I-binding 9-mer peptides in Mtb72F were predicted
for the A*02:01, A*03:01 and B*07:02 alleles (representing
the HLA-I supertypes A02, A03 and B07 respectively
[38]). Collectively these supertypes have been reported to
cover 80–90 % of any given human population worldwide,
regardless of ethnicity [39].
Using NetMHCpan-2.2, the combined numbers of
strong and weak binders predicted for A*02:01, A*03:01
and B*07:02 were 23, 2 and 15, respectively (Additional
file 3). The 11 strong binders predicted by this algo-
rithm, and the 10 high-affinity binders predicted by
NetCTLpan-1 were all restricted to A*02:01 or B*07:02.
Table 3 Prediction of HLA II-binding peptides for DRB3/4/5, DP
and DQ alleles
HLA molecule Mtb32A Mtb39A Mtb72F M72
DRB3*01:01 18 7 31 31
DRB3*02:02 19 56 71 71
DRB3*03:01 51 82 125 125
DRB4*01:01 27 38 58 58
DRB5*01:01 32 85 109 109
DRB5*01:02 45 107 145 145
DQA1*05:01-DQB1*02:01a 14 35 51 51
DQA1*02:01-DQB1*02:01b 0 0 0 0
DQA1*05:01-DQB1*03:01a 291 325 614 610
DQA1*03:01-DQB1*03:02a 17 75 88 88
DQA1*04:01-DQB1*04:02a 15 75 87 88
DQA1*01:01-DQB1*05:01a 8 0 1 1
DQA1*01:02-DQB1*05:02 26 37 61 61
DQA1*01:02-DQB1*06:02a 161 262 392 392
DPA1*02:01-DPB1*01:01c 27 33 56 56
DPA1*01:03-DPB1*02:01c 20 23 39 39
DPA1*01:03-DPB1*04:01c 14 11 16 16
DPA1*01:03-DPB1*04:02c 18 17 28 28
DPA1*02:02-DPB1*05:01b, c 8 0 0 0
DPA1*02:01-DPB1*14:01 50 128 170 170
Prediction results represent the sum of the weak and strong binders. a Allele
is among the 6 HLA-DQ molecules that reportedly are present in >85 % of
populations worldwide [32]. b For these alleles, no frequencies are reported in the
populations assessed (Additional file 2). c Allele is among the 5 HLA-DP molecules
that reportedly are present in >90 % of populations worldwide [33]
Table 4 Impact of the alterations introduced for the Mtb72F constru
Alteration introduced in Mtb72F Change in the numbers o
covereda alleles for Mtb72
Deletion of the Mtb32A signal sequence. Loss of 1 covered allele
containing 28 predicted
epitopes
Splitting the Mtb32A sequence upstream and
downstream of ‘TAAS’ sequence.
No changes in the numbe
of covered alleles.
Addition of a poly-His tag (MHHHHHH) at the
Mtb32A C-terminal end.
No changes in the numbe
of covered alleles.
Addition of 2-amino acid hinge sequences at the
junction sites between Mtb32C and Mtb39A (EF),
and between Mtb39A and Mtb32N (DI).
No changes in the numbe
of covered alleles.
a Covered allele: an allele for which at least one epitope was predicted
Mortier et al. BMC Immunology  (2015) 16:63 Page 7 of 14Higher numbers of binding peptides (78 in total, of
which 48 strong binders) were predicted by the com-
bined 5 other algorithms that were used.
Discussion
This in silico study explored the sequence conservation of
Mtb32A, Mtb39A, Mtb72F and the current candidate vac-
cine antigen M72, and predicted MHC-I and/or MHC-II-
binding peptides for these proteins. Our results led to two
main conclusions. First, the Mtb32A and Mtb39A pro-
teins (and thus also the Mtb72F and M72 constructs) ap-
peared to be well conserved (with at least 98 % identity)
among the strains representative for the major part of the
Mtb geographical distribution (including MDR, XDR and
pre-XDR strains), with for Mtb39A a higher sequence
conservation than previously reported in [26, 27]. Second,
the putative CD4+ T-cell epitopes predicted for Mtb72F
and M72 were shown to cover a broad range of HLA
Class II DRB1, DRB3/4/5, DQ and DP alleles, and the pu-
tative CD8+ T-cell epitopes predicted for Mtb72F covered
each of the HLA-A or -B alleles assessed.
Hyperconservation has been reported for the large ma-
jority of human T-cell epitopes in the Mtb complex, al-
though pe/ppe genes were excluded from that study [40].
Previously, mtb32a sequences of H37Ra, H37Rv, Erdman
and the clinical isolate CSU93 were found to be identical
[13], and, extending these studies, Mtb32A was shown to
be relatively well conserved among several clinical isolates,
with amino acid changes in only 6 % of the 225 investi-
gated strains [28]. Consistently, our data revealed a high
level of conservation for Mtb32A. For Mtb39A, our find-
ings contrast with previous studies which suggested a sub-
stantial genetic variation for this protein, potentially
associated with the homologous recombination with ppe19
and ppe60 [28, 29]. Nonetheless, several of the minor inser-




Epitopes in the Mtb32A signal sequence were predicted for 149 of
the 158 alleles assessed. For 148 of the 149 alleles, epitopes were also
predicted for the other parts of the protein. Only for 1 allele (DRB1*16:04),
all 28 predicted epitopes were located in the Mtb32A signal sequence,
and were thus not predicted for Mtb72F.
r For each allele with an epitope predicted in this part of the protein
there was also an epitope predicted in other parts of the protein.
There was an overall loss of 14 predicted epitopes.
r One epitope (MHHHHHHTAASDNFQ, binding to DRB1*08:18)
was predicted for the Meth-His tag in Mtb72F. There were also
other epitopes predicted for this allele.
r Adding the EF and DI sequences resulted in 13 and 5 additional
predicted epitopes, binding to 43 and 31 alleles, respectively.
However, the number of alleles with at least one predicted
epitope did not change.
Table 5 Comparison of experimentally-defined and predicted 15-mer HLA class II-binding peptides for three DRB1 alleles
Performance algorithm DRB1*0101 (DR1) DRB1*1501 (DR2) DRB1*0401 (DR4)
Mtb32A Mtb39A Mtb72F Mtb32A Mtb39A Mtb72F Mtb32A Mtb39A Mtb72F
INAFSVGSGQTYGVD VNEAEYGEMWAQDAA LSQDRFADFPALPLD MLKGFAPAAAAQAVQ LNGLIQFDAAIQPGD TAYGLTVPPPVIAEN
GSGQTYGVDVVGYDR AYETAYGLTVPPPVI DRFADFPALPLDPSA KTVSPHRSPISNMVS NFQLSQGGQGFAIPI VVWGLTVGSWIGSSA
ATDINAFSVGSGQTY AEYGEMWAQDAAAMF APAQAAPPALSQDRFa MSSLGSSLGSSGLGG LNGHHPGDVISVTWQ GLTVGSWIGSSAGLM
YDRTQDVAVLQLRGA GEMWAQDAAAMFGYA SSAGLMVAAASPYVA LTNNHVIAGATDINA GVAANLGRAASVGSL
VAVLQLRGAGGLPSA AAAAYETAYGLTVPP QTYGVDVVGYDRTQD ANLGRAASVGSLSVP
GGQGGTPRAVPGRVV ASVGSLSVPQAWAAA VPGRVVALGQTVQAS AAAAYETAYGLTVPP
QTYGVDVVGYDRTQD VVWGLTVGSWIGSSA IPIGQAMAIAGQIRS ASAFQSVVWGLTVGS
FSVGSGQTYGVDVVG VRVAAAAYETAYGLT NGARVQRVVGSAPAA VTPAARALPLTSLTS





































Table 5 Comparison of experimentally-defined and predicted 15-mer HLA class II-binding peptides for three DRB1 alleles (Continued)
Total binders determined
in vitro
9 14 23 3 4 6 29 32 60
Total non-bindersb 106 113 202 112 123 219 86 95 165
True predicted binders
(TP)
5 12 17 0 2 2 4 13 17
True predicted
non-binders (TN)
45 28 68 102 108 197 77 70 134
Sensitivity prediction
algorithm
55 % 86 % 74 % 0 % 50 % 33 % 14 % 41 % 28 %
Specificity prediction
algorithm
42 % 25 % 34 % 91 % 88 % 90 % 90 % 74 % 81 %
Listed epitopes were derived from ref. [18] and experimentally found to bind MCH Class II molecules. Peptides predicted by NetMHCpan-3.0 in the current study are underlined and highlighted in bold. TP True positives. In ref.
[18] and the current study, data were generated using 15 mer peptides overlapping by 12 mer. TN True negatives. aSequence does not appear in the Mtb72F recombinant protein. bLength of the Mtb72F sequence is 729
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aa deletions at the 274th base, in repeat regions in 1 and 6
strains, respectively) may be identical to those reported for
Arkansas-derived samples in the above study [28]. Of the
frameshifts leading to major amino acid changes, as we ob-
served in 3 strains, the one in the avirulent H37Ra strain
was consistent with earlier findings [41] and of little clinical
relevance, while the one in EAS054 has not been reported
previously to the best of our knowledge. Possibly, the num-
ber and origin of the strains evaluated here reflect the
worldwide prevalence of Mtb more accurately than those
used in the referenced studies, which included 225 US and
Turkey-derived clinical strains [28], or 16 clinical isolate
sequences from a public database [29]. As we have not
assessed whether the minor insertions and/or deletions
coincide with locations of predicted putative epitopes, the
impact of the associated residue changes on the recogni-
tion of clinical Mtb strains by T-cell responses induced by
Mtb72F or M72 candidate vaccines, is not known.
MHC-II binding peptides in Mtb72F were predicted to
cover all DRB1, DRB3/4/5, DQ and DP alleles assessed,
except for 2 DRB1 alleles (03:02 and 16:04), 1 DQ and 1
DP allele. Based on the used database, this DP allele
(DPA1*02:02-DPB1*05:01) does not occur in the popu-
lations assessed, while the DQ allele (DQA1*02:01-
DQB1*02:01) only prevails in these populations in
haplotype with DRB1*07:01, which was predicted to be
well covered with binding peptides. Several aspects are
important to consider with respect to the implications
of the absence of predicted binding peptides for the
two DRB1 alleles for the candidate vaccines’ potential
efficacy in the populations concerned. First, except for
the higher frequency of DRB1*03:02 in certain Sub-
Saharan African populations (≤17.2 %) as compared
with the worldwide genotypic frequency of 1.1 % [37],
the associated allele frequencies were generally low in these
populations (≤1.5 %). Moreover, a potential absence of
binding peptides for the two DRB1 alleles in these popula-
tions may be compensated by peptides present on other
HLA-DR, −DP or -DQ alleles, and vice versa. For instance,
for the South-African Limpopo Venda population,
DRB1*13:02 and DQB1*03:01–03:04 have been associated
with TB disease [42]. In this population, the frequency of
DRB1*03:02 is relatively high (9 %). The absence of binding
peptides for DRB1*03:02 may in this case be compensated
by several other alleles prevailing at high frequencies in this
population (e.g., DRB1*11, DRB1*03:01, DRB1*13:01,
DRB*01 and DQB1*06 and DQB1*05; data retrieved from
[36]), for which we predicted high numbers of binding
peptides per allele in Mtb72F. It may also be reassuring
that in a recent clinical trial, the candidate vaccine M72/
AS01 was able to induce robust CD4+ T-cell responses in
healthy adults in South Africa [22]. Furthermore, it is
noted that for other antigens (meningococcal serogroup Bproteins) it was shown that a set of only 2 predicted T-cell
epitopes could theoretically cover large proportions of over
11 populations worldwide [43]. A confounding factor is
that the allele frequencies sourced from a public database
may have only partial or local coverage (e.g. cities or ethnic
groups), since they are usually based on relatively small
sample sizes rather than population statistics. Similarly,
since certain alleles specific to susceptible populations have
likely been the prime focus of several studies, the database
may contain disproportionally high numbers of such
alleles.
Although our data showed that the changes intro-
duced in Mtb32A in order to construct Mtb72F may
result in an overall reduction of Mtb binding peptides,
only two alleles present in the populations assessed
(DRB1*03:02 and 16:04) were predicted to have no bind-
ing peptide in Mtb72F. The other modifications (addition
of hinge sequences and a poly-His tag) were predicted to
jointly generate 19 binding peptides, of which one peptide
was predicted to be absent in M72. Since non-Mtb epi-
topes do not contribute to the vaccine’s ability to induce
Mtb-specific responses, their relatively low frequency in
Mtb72F and M72 is reassuring.
Previously, in silico MHC-II binding predictions for
9-mer peptides in Mtb72F have been generated for 34
DRB1 alleles [26, 27]. Comparison of the previous data
with the present predictions for 15-mer peptides and
DRB1 alleles revealed up to 37-fold differences in the
allele-matched binding peptide numbers, which can
likely for a great part be explained by the different
binding peptide lengths assumed by the prediction al-
gorithm. HLA-I and HLA-II binding peptides are com-
posed of 8–10 and 13–17 amino acids respectively [44].
The peptide-binding groove of MCH-II molecules is
open-ended, which complicates identification of the 9-
mer core peptides and the flanking residues (which
may also contain predictive information [45]). MHC-II
prediction algorithms assuming 9-mer binding peptides
do not use information present outside the core, lead-
ing to lower accuracy [46]. Consistently, it was shown
that including flanking residues among inputs im-
proved the performance of MHC-II prediction methods
[47, 48]. However, even predictions generated by algo-
rithms assuming 15-mer binding peptides may have
limited reproducibility, as suggested by the present re-
sults. Indeed, comparison of our results for Mtb32A
and Mtb39A with allele-matched experimental binding
data [18] revealed that the algorithm’s sensitivity and
specificity were variable and occasionally rather low for
Mtb72F (e.g., 28 %). It is noted though that due to the
lack of additional suitable in vitro data, this comparison
covered only 3 of the 158 HLA-DRB1 alleles, and none
of the DRB3/4/5, DQ and DP alleles assessed in our
study. While the observed variability in the
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the limited extent of this evaluation, it could therefore
also be inherent to the limitations of the used predic-
tion algorithms for peptide binding in general. Simi-
larly, most algorithms predicting T-cell activation for
class II binding peptides display low sensitivity, as less
than half of the defined T-cell activating peptides were
predicted to be binders [46]. Thus, epitope identifica-
tion requires an integrated approach, in which in silico
binding predictions are complemented with confirma-
tory biochemical verification of MHC processing and
binding, and of the ability of the predicted peptides to
induce T-cell responses [49]. Other useful tools are in
silico methods that enable linking binding affinity pat-
terns to topological characteristics [50].
Due to the capped MHC-I peptide binding groove, this
binding is more specific than binding to MHC-II, and
HLA-I binding prediction algorithms are considered
relatively accurate [46, 49]. Indeed, there was only at
most a five-fold difference between the previously re-
ported numbers of HLA A- and B-binding peptides in
Mtb72F [27] and the numbers per allele computed here.
In the present study, the majority of predicted peptides
were presented by A*02:01, listed in the IEDB among the
most frequent HLA class I alleles in regions with high TB
incidence [4]. The predicted high affinity-binders were
mainly presented by A*02:01 and B*07:02 rather than
A*03:01, consistent with data obtained for a panel of 432
H37Rv-derived peptides [5], while other Mtb proteins (e.g.
Mtb8.4, CFP10 and Ag85B) were shown, experimentally or
in silico, to be primarily presented by various HLA-B mole-
cules [51, 52]. Furthermore, our data showing the predicted
binding of the Mtb72F peptides APINSATAM, APAAAA-
QAV, LLGQNTPAI and SSKLGGLWK to B*07:02, B*07:02,
A*02:01 and A*03:01 respectively corroborates earlier pre-
dictions for these peptides [5]. Of note, several previously
predicted HLA I-restricted Mtb peptides were experimen-
tally shown to induce CD4+ rather than CD8+ T cell re-
sponses [53]. Similarly, the HLA-B44-restricted epitope
MWAQDAAAMF [16], was also found in two 15-mer
Mtb39A peptides that were experimentally defined [18] and
predicted here to bind to DRB1*04:01 and/or 01:01.
Last, for cytomegalovirus antigens, it has been suggested
that less than 20 uniquely defined HLA-restricted CD8+ T-
cell epitopes could provide 90 % coverage of the three major
ethnic groups [54]. Possibly, the putative class I Mtb epi-
topes predicted for Mtb72F could also have a wide coverage
of populations worldwide, and, given that only minor
changes were introduced into Mtb72F to generate M72, this
would also apply to M72.
Conclusions
Mtb72F and M72 sequences were shown to be highly
conserved among Mycobacterium strains including MDRand XDR strains, and are thus expected to provide broad
coverage of the pathogen population. For Mtb72F, the
predicted MHC-II binding peptides covered a wide array
of HLA-DRB1, −DQ and -DP alleles, whereby the ab-
sence of predicted binding peptides for 2 DRB1 alleles
prevailing in some populations with high TB burden
may be compensated by peptides binding to other HLA
loci. MHC-I binding peptides were predicted for each
HLA-A/B allele assessed. Yet, discrepancies between the
current predictions and experimental HLA-binding data
underscore the limitations inherent in interpreting in
silico predictions for HLA class II-restricted peptides.
Experimental epitope verification, by determination of
the HLA-binding capacity of synthetic peptides and of
their correct processing, remains valuable. Also, their
immunogenicity could be confirmed by identification of
T cells specific for the epitope, using PBMCs from HLA-
typed subjects.Methods
Mtb72F and M72 vaccine antigens
Mtb72F is a 729-aa, 72-kDa polyprotein derived from
Mtb32A and Mtb39A (encoded by Rv0125 and Rv1196, re-
spectively). The full nucleotide and deduced amino acid se-
quences of Mtb32A, Mtb39A and Mtb72F have been
described [12–14]. Mtb72F has been constructed in the
linear order (starting at the amino end): carboxyl-terminal
portion of Mtb32A (Mtb32C) - full-length ORF of Mtb39A
- N-terminal fragment of Mtb32A excluding the signal se-
quence (Mtb32N). Since the Mtb32A sequence has been
split upstream and downstream of the TAAS sequence
linking the Mtb32C and Mtb32N sequences, TAAS is
present in Mtb72F at the N-terminal end of Mtb32C as
well as at the C-terminal end of Mtb32N. In summary,
the following changes were made compared to the na-
tive Mtb32A protein: (i) addition of nucleotide se-
quences encoding a poly–His tag (MHHHHHH) at the
Mtb72F N-terminus; (ii) deletion of the 32-aa signal se-
quence (MSNSRRRSLRWSWLLSVLAAVGLGLATAPA
QA) located at the Mtb32 N-terminus; (iii) addition of
two hinge sequences (an EcoRI restriction site, located
between Mtb32C and Mtb39A, and an EcoRV restric-
tion site between Mtb39A and Mtb32N) resulting in the
EF and DI residues in Mtb72F, respectively (one at each
junction site).
M72 was generated by introducing a point mutation in
Mtb72F, thereby replacing Ser706 by Ala706, and by chan-
ging the poly-His tag of Mtb72F into the MHH sequence
present in M72.
Sequence alignments and similarity analyses
Using the BLAST program [55], Mtb protein sequences
available in the NCBI GenPept database (accessed February
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Mtb39A sequence. The selection of 44 and 42 genomes for
Mtb32A and Mtb39A respectively comprised the laboratory
strain H37Ra, as well as M. africanum and clinical isolates
from presently available Mtb strains including MDR, XDR
and pre-XDR strains (i.e., Mtb Beijing family strains and
North and South-American, African, Asian, and European
strains). To the extent the information was available, the
strains were matched with a detailed molecular phylogeny
of the Mtb complex [30], which divides the global popula-
tion structure of Mtb strains in 6 main phylogeographical
lineages. Our selection included predominant strains from
each main lineage, with the exception of Lineage 3 (India/
East Africa) for which no strains were included (Table 1).
Complete genomes, or assembled partial genomes
when validated and/or complete genomes were unavail-
able, were downloaded from the GenBank database. For
the 40 strains for which both the Mtb32A and Mtb39A
sequences were available, the genomes were used for the
construction of Mtb72F and M72 as described above
(see ‘Mtb72F and M72 vaccine antigens’), excluding the
additional residues at the junction sites and the Mtb72F/
M72 poly-His tag). To ensure that the used sequence
was specific for mtb39, rather than for one of the known
mtb39 paralogs (ppe19 and ppe60), a fragment containing
Mtb39A with PE13 upstream, and ESAT-6-like (esxL)
downstream, was extracted from the TB genomes. Mtb39A
nucleotide sequences from 42 strains were translated into
amino acid sequences, which were subsequently compared
by multiple alignments using ClustalX software. For
Mtb72F and M72, all protein sequences had very similar or
identical lengths. Similarity analyses for Mtb32A, Mtb39A,
Mtb72F and M72 were done by multiple alignment com-
parisons. Percentage identity between the sequences was
defined as ‘(number of identical residues / length of align-
ment) x 100’. The data for Mtb39A were also analysed sep-
arately for the presence of nucleotide and amino acid
changes (insertions, deletions and/or frameshifts).
DRB, DP and DQ allele frequencies
MHC-II peptide binding predictions were done for HLA-
DRB1, DRB3/4/5, DQ and DP alleles, whereby the DRB1
allele frequencies characterizing the populations in each
region were extracted from the ‘Allele*frequencies in
Worldwide Populations’ database [36] (http://www.allele-
frequencies.net; accessed November 2013). The 158 DRB1
alleles evaluated (including the common alleles 01:01,
03:01, 04:01, 07:01, 11:01 and 15:01) comprised 146, 47,
25, 42 and 66 alleles present in populations in China,
North India, Southern India, North-Eastern India and
Sub-Saharan Africa (native population), respectively. India
and China, and 9 Sub-Saharan African countries are
among the 22 high-TB burden regions defined by the
World Health Organization [56]. The discrimination ofNorthern, Southern, and North-Eastern Indian regions
was based on the local prevalent population structures,
while for the Chinese and Sub-Saharan African regions in-
sufficient information was available to apply further detail-
ing. The 8 HLA-DQ molecules assessed contained the 6
molecules that reportedly are present in over 85 % of pop-
ulations worldwide [32], and the 6 HLA-DP molecules
assessed contained the 5 HLA-DP molecules that report-
edly are present in >90 % of populations worldwide [33]
(see Table 3). Frequencies of alleles for which no binding
peptides were predicted in this study were extracted from
the above-mentioned public database [36]; accessed 26
January 2015). HLA-I binding predictions were done for
A*02:01, A*03:01 and B*07:02, which were selected by the
developers of the NetMHCpan-2.2 algorithm to represent
the supertypes A02, A03 and B07 respectively [38, 57].
Collectively these supertypes have been reported to cover
83–88 % of 5 major ethnic groups worldwide [39].
HLA class II-binding peptide predictions for DRB, DP and
DQ alleles
HLA-II binding predictions were generated for 15-mer
peptides (overlapping by 14 amino acids) of Mtb32A,
Mtb39A and Mtb72F using NetMHCIIpan-3.0 [58], and
for the 158 DRB1, 6 DRB3/4/5, 6 DP and 8 DQ alleles de-
scribed. The Mtb72F construct was produced in silico as
described above (see ‘Mtb72F and M72 vaccine antigens’)
with exclusion of the poly-His sequence. In addition,
the potential impact of the alterations introduced for
the Mtb72F and M72 constructions on the prediction
results was evaluated. For DRB1*01:01, DRB1*04:01 and
DRB1*15:01, data were also generated using 15 mer
peptides overlapping by 12 amino acids. Results were com-
pared with previously published experimental data for 15-
mer Mtb peptides (overlapping by 12 amino acids) binding
to these 3 alleles [18], using the Mtb72F sequence with ex-
clusion of the hinge sequences and poly-His tag. As recom-
mended by the program, a peptide was identified as a
‘strong binder’ if the binding affinity [IC50] was below 50
nM or as a ‘weak binder’ if the IC50 was >50 nM but <500
nM. The total numbers of epitopes shown in this study
represent the sum of the strong and the weak binders.
HLA class I-binding peptide predictions
MHC-I-binding predictions for the A*02:01, A*03:01
and B*07:02 alleles were done for 9-mer peptides in
Mtb72F using NetCTLpan-1 [59], NetMHCpan-2.2 [57],
SVMHC, Syfpeithi [2], EpiJen [60], nHLA-pred (nHLA-
compred and nHLA-aanpred) and NetCTL-1.2 [61]. Re-
sults are presented as the individual outputs of
NetCTLpan-1 and NetMHCpan-2.2 (which have been
reported as having a higher accuracy [57, 59]) or as
grouped outputs for the other programs used. Positive
results generated by NetCTLpan were assigned ‘*’ if the
Mortier et al. BMC Immunology  (2015) 16:63 Page 13 of 14putative epitopes were correctly processed (proteasome
and transporters associated with antigen processing
[TAP]) and bound to the MHC. For all other programs,
positive results were classified based on binding strength
to the MHC, either as strong or weak binders (‘SB’ or
‘WB’, respectively) based on the author-recommended
cut-offs.
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